What is a stock summary page? Click here for an overview.
Business Description
Immunovia AB
ISIN : SE0006091997
Compare
Compare
Traded in other countries / regions
IMMNOV.Sweden0G8X.UK1YR.GermanyIMMVF.USA IPO Date
2018-01-25Description
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.23 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -51.21 | |||||
| Beneish M-Score | -0.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -13.5 | |||||
| 3-Year EBITDA Growth Rate | 35.5 | |||||
| 3-Year EPS without NRI Growth Rate | 33.6 | |||||
| 3-Year FCF Growth Rate | 31.2 | |||||
| 3-Year Book Growth Rate | -80.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 56.83 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 224.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.06 | |||||
| 9-Day RSI | 17.94 | |||||
| 14-Day RSI | 19.42 | |||||
| 3-1 Month Momentum % | -37.5 | |||||
| 6-1 Month Momentum % | -53.96 | |||||
| 12-1 Month Momentum % | -56.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.82 | |||||
| Quick Ratio | 1.82 | |||||
| Cash Ratio | 1.61 | |||||
| Days Sales Outstanding | 57.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51.2 | |||||
| Shareholder Yield % | -48.05 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -11751.99 | |||||
| Net Margin % | -8221.38 | |||||
| FCF Margin % | -10392.37 | |||||
| ROE % | -211.86 | |||||
| ROA % | -118.08 | |||||
| ROIC % | -285.18 | |||||
| 3-Year ROIIC % | -27.62 | |||||
| ROC (Joel Greenblatt) % | -604.71 | |||||
| ROCE % | -145.77 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 0.1 | |||||
| PS Ratio | 28.44 | |||||
| PB Ratio | 3.71 | |||||
| Price-to-Tangible-Book | 4.39 | |||||
| EV-to-EBIT | -0.8 | |||||
| EV-to-EBITDA | -1.05 | |||||
| EV-to-Revenue | 47.1 | |||||
| EV-to-FCF | -0.44 | |||||
| Price-to-GF-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 6.59 | |||||
| Price-to-Net-Cash | 13.18 | |||||
| Earnings Yield (Greenblatt) % | -125.61 | |||||
| FCF Yield % | -141.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunovia AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.931 | ||
| EPS (TTM) (kr) | -1.028 | ||
| Beta | 0.5 | ||
| 3-Year Sharpe Ratio | -0.59 | ||
| 3-Year Sortino Ratio | -0.9 | ||
| Volatility % | 122.65 | ||
| 14-Day RSI | 19.42 | ||
| 14-Day ATR (kr) | 0.005977 | ||
| 20-Day SMA (kr) | 0.2967 | ||
| 12-1 Month Momentum % | -56.31 | ||
| 52-Week Range (kr) | 0.262 - 1.022 | ||
| Shares Outstanding (Mil) | 261.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunovia AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunovia AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Immunovia AB Frequently Asked Questions
What is Immunovia AB(LTS:0G8X)'s stock price today?
The current price of LTS:0G8X is kr0.26. The 52 week high of LTS:0G8X is kr1.02 and 52 week low is kr0.26.
When is next earnings date of Immunovia AB(LTS:0G8X)?
The next earnings date of Immunovia AB(LTS:0G8X) is 2025-05-14.
Does Immunovia AB(LTS:0G8X) pay dividends? If so, how much?
Immunovia AB(LTS:0G8X) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers